These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10641986)

  • 1. The challenge of managing mild Parkinson's disease.
    LeWitt PA
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):2S-7S. PubMed ID: 10641986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract]   [Full Text] [Related]  

  • 3. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Montgomery EB
    Neurology; 2004 Jan; 62(2):343; author reply 343-5. PubMed ID: 14745094
    [No Abstract]   [Full Text] [Related]  

  • 4. Should treatment of Parkinson's disease be started with a dopamine agonist?
    Poewe W
    Neurology; 1998 Aug; 51(2 Suppl 2):S21-4. PubMed ID: 9711976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice. Diagnosis and initial management of Parkinson's disease.
    Nutt JG; Wooten GF
    N Engl J Med; 2005 Sep; 353(10):1021-7. PubMed ID: 16148287
    [No Abstract]   [Full Text] [Related]  

  • 6. Tremor and dopamine agonists.
    Elble RJ
    Neurology; 2002 Feb; 58(4 Suppl 1):S57-62. PubMed ID: 11909986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 9. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 10. Old and new dopamine agonists in Parkinson's disease. Proceedings of an international congress. Pisa, Italy, December 1993.
    J Neural Transm Suppl; 1995; 45():1-321. PubMed ID: 8847537
    [No Abstract]   [Full Text] [Related]  

  • 11. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptor agonists in the therapy of Parkinson's disease.
    Foley P; Gerlach M; Double KL; Riederer P
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1375-446. PubMed ID: 15480844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early Parkinson's disease.
    Dickerson LM; Young SE; Simpson WM; Nashelsky J
    Am Fam Physician; 2005 Aug; 72(3):497-500. PubMed ID: 16100865
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 16. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 17. Newer therapies for Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Neurol Neurochir Pol; 1996; 30 Suppl 2():105-11. PubMed ID: 9100248
    [No Abstract]   [Full Text] [Related]  

  • 18. What is the best initial treatment in Parkinson's disease?
    Sharp ME; Mazzoni P
    J R Coll Physicians Edinb; 2014; 44(4):291-2. PubMed ID: 25516899
    [No Abstract]   [Full Text] [Related]  

  • 19. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease.
    Pirtosek Z; Merello M; Carlsson A; Stern G
    Adv Neurol; 1996; 69():535-40. PubMed ID: 8615177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.